en · de · es · fr · pt
cardarine-notes.peptides6908.com › News › Mechanism And Safety Research — Questions and Answers

Mechanism And Safety Research — Questions and Answers

By Editorial Desk · published 2026-07-20 · last reviewed 2026-08-01 · News

fatty acid oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδNuclear receptor; not androgen receptor
Studied indicationsDyslipidemia; obesity; diabetesEarly clinical research; development discontinued
Rodent toxicityTumor formation in multiple tissuesDose-dependent findings in some studies
Human approvalNoneNo approved therapeutic use
Typical analytical methodLC-MS/MSUsed for identity and quantification

Regulatory Status and Detection Context

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Related pages on this site

Regulation and Detection

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

Mechanism and Detection Methods

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.

Background from the literature

The project was suggested to and given the green light by Mazda's Senior Managing Director Keiji Asano while he was on a trip to Indonesia in 1986. Sold alongside the seventh generation 323, an MR90 cost less than half the price of the newer model, but still more expensive than Toyota Kijang and Suzuki Carry "minibuses" as the country imposed 30% tax for saloons. In the past hatchback and wagon were classified as sedan Indonesia, but then revised as "minibus" in early 2000s. This changes boosting the sales of hatchbacks and started the downfall of sedans popularity in Indonesia.

==== MeSH D12.125.068 – amino acids, basic ==== MeSH D12.125.068.050 – arginine MeSH D12.125.068.050.075 – argininosuccinic acid MeSH D12.125.068.050.095 – benzoylarginine-2-naphthylamide MeSH D12.125.068.050.100 – benzoylarginine nitroanilide MeSH D12.125.068.050.400 – homoarginine MeSH D12.125.068.050.525 – ng-nitroarginine methyl ester MeSH D12.125.068.050.587 – nitroarginine MeSH D12.125.068.050.650 – omega-n-methylarginine MeSH D12.125.068.050.900 – tosylarginine methyl ester MeSH D12.125.068.060 – asparagine MeSH D12.125.068.330 – glutamine MeSH D12.125.068.330.700 – proglumide MeSH D12.125.068.555 – lysine MeSH D12.125.068.555.478 – hydroxylysine MeSH D12.125.068.555.575 – lysinoalanine MeSH D12.125.068.555.750 – polylysine MeSH D12.125.068.665 – ornithine MeSH D12.125.068.665.340 – eflornithine

The minerals, results of biomineralization processes regulated by the environment or bacteria, are also essential components of the exopolysaccharides. They provide structural integrity to biofilm matrix and act as a scaffold to protect bacterial cells from shear forces and antimicrobial chemicals. The minerals in EPS were found to contribute to morphogenesis of bacteria and the structural integrity of the matrix. For example, in Bacillus subtilis, Mycobacterium smegmatis, and Pseudomonas aeruginosa biofilms, calcite (CaCO3) contributes to the integrity of the matrix. The minerals also associate with medical conditions. In the biofilms of Proteus mirabilis, Proteus vulgaris, and Providencia rettgeri, the minerals calcium and magnesium cause catheter encrustation.

Sources: en.wikipedia.org

Further detail

Intradialytic parenteral nutrition (IDPN) is a nutritional support therapy (medical nutrition therapy) for people on hemodialysis who have a difficult time maintaining adequate nutrition. It is administered directly into the bloodstream of patients with chronic kidney disease (CKD) in an effort to decrease the associated morbidity and mortality experienced in patients with kidney failure. IDPN contains protein (amino acids), carbohydrates (dextrose), and fats (lipids) in an attempt to meet a patient's weekly nutritional needs. Solutions can be individualized for each patient based on weight, needs, medical history and enteral intake.

Roentgenium (German: [ʁœntˈɡeːni̯ʊm] ) is a synthetic chemical element; it has symbol Rg and atomic number 111. It is extremely radioactive and can only be created in a laboratory. The most stable known isotope, roentgenium-282, has a half-life of 130 seconds, although the unconfirmed roentgenium-286 may have a longer half-life of about 10.7 minutes. Roentgenium was first created in December 1994 by the GSI Helmholtz Centre for Heavy Ion Research near Darmstadt, Germany. It is named after the physicist Wilhelm Röntgen (also spelled Roentgen), who discovered X-rays. Only a few roentgenium atoms have ever been synthesized, and they have no practical application. In the periodic table, it is a d-block transactinide element. It is a member of the 7th period and is placed in the group 11 elements, although no chemical experiments have been carried out to confirm that it behaves as the heavier homologue to gold in group 11 as the ninth member of the 6d series of transition metals. Roentgenium is calculated to have similar properties to its lighter homologues, copper, silver, and gold, although it may show some differences from them.

In 1838, France enacted a law to regulate both the admissions into asylums and asylum services across the country. In the United States, the erection of state asylums began with the first law for the creation of one in New York, passed in 1842. The Utica State Hospital was opened around 1850. Many state hospitals in the United States were built in the 1850s and 1860s on the Kirkbride Plan, an architectural style meant to have curative effect. At the turn of the century, England and France combined had only a few hundred individuals in asylums. By the late 1890s and early 1900s, this number had risen to the hundreds of thousands. However, the idea that mental illness could be ameliorated through institutionalization ran into difficulties. Psychiatrists were pressured by an ever-increasing patient population, and asylums again became almost indistinguishable from custodial institutions. In the early 1800s, psychiatry made advances in the diagnosis of mental illness by broadening the category of mental disease to include mood disorders, in addition to disease level delusion or irrationality. The 20th century introduced a new psychiatry into the world, with different perspectives of looking at mental disorders. For Emil Kraepelin, the initial ideas behind biological psychiatry, stating that the different mental disorders are all biological in nature, evolved into a new concept of "nerves", and psychiatry became a rough approximation of neurology and neuropsychiatry.

(2026) present a dataset of ages obtained through radiocarbon dating by accelerator mass spectrometry of bone collagen from remains of late Quaternary mammalian megafauna from Eurasia and North America. Review of advances in the study of paleogenomics of Chinese Quaternary proboscideans, even- and odd-toed ungulates and large carnivorans from the preceding years is published by Sheng et al. (2026). Köhler (2026) reviews the evolution of traits of organims from inland environments (including extinct Myotragus) that are adaptations to life in low-mortality isolated ecosystems with limited resources, and notes similarities with the evolution of traits of organisms adapted to life in caves. Schowanek et al. (2026) study factors influencing survival probability of mammals living in tropical forests of Africa, the Americas and the Indomalayan realm during the past 130,000 years, and report that analyses utilizing different statistical models recover similar predictors of extinction risk at the global scale, but recover variable predictors of extinction risk at smaller spatial scales. Kennedy & Sumanarathna (2026) present the first three-dimensional palaeoart reconstructions of Palaeoloxodon namadicus sinhaleyus and the Quaternary rhinoceros from the Sabaragamuwa Basin (Sri Lanka) historically referred to as Rhinoceros sinhaleyus. Faria et al.

Sources: en.wikipedia.org

Background from the literature

In biochemistry and pharmacology, receptors are proteins that receive and transduce signals that may be integrated into biological systems. These signals are typically chemical messengers which bind to a receptor and produce physiological responses, such as a change in the electrical activity of a cell. For example, GABA, an inhibitory neurotransmitter, inhibits electrical activity of neurons by binding to GABAA receptors. There are three main ways the action of the receptor can be classified: relay of signal, amplification, or integration. Relaying sends the signal onward, amplification increases the effect of a single ligand, and integration allows the signal to be incorporated into another biochemical pathway. Receptor proteins can be classified by their location. Cell surface receptors, also known as transmembrane receptors, include ligand-gated ion channels, G protein-coupled receptors, and enzyme-linked hormone receptors. Intracellular receptors are those found inside the cell, and include cytoplasmic receptors and nuclear receptors. A molecule that binds to a receptor is called a ligand and can be a protein, peptide (short protein), or another small molecule, such as a neurotransmitter, hormone, pharmaceutical drug, toxin, calcium ion or parts of the outside of a virus or microbe. An endogenously produced substance that binds to a particular receptor is referred to as its endogenous ligand. E.g. the endogenous ligand for the nicotinic acetylcholine receptor is acetylcholine, but it can also be activated by nicotine and blocked by curare.

C-reactive protein (CRP) is an annular (ring-shaped) pentameric protein found in blood plasma, whose circulating concentration rises in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via C1q. CRP is synthesized by the liver in response to factors released by macrophages, T cells and fat cells (adipocytes). It is a member of the pentraxin family of proteins. It is not related to C-peptide (insulin) or protein C (blood coagulation). C-reactive protein was the first pattern recognition receptor (PRR) to be identified.

Np(V) or NpO+2 is green-blue in aqueous solution, in which it behaves as a strong Lewis acid. It is a stable ion and is the most common form of neptunium in aqueous solutions. Unlike its neighboring homologues UO+2 and PuO+2, NpO+2 does not spontaneously disproportionate except at very low pH and high concentration:

== Second Ministry == On 9 January 1997, the Governor, Major General Michael Jeffery, designated 17 principal executive offices of the Government under section 43(2) of the Constitution Acts Amendment Act 1899. The following ministers were then appointed to the positions, and served until the reconstitution of the Ministry on 22 December 1999.

Evidence from the study of extant Japanese macaques, indicating that the initial shift from quadrupedalism to bipedalism in the hominin evolution might have involved a shift of the primary action of the gluteus medius without any required morphological change, is presented by Shitara et al. (2026). Sekhavati, Prang & Strait (2026) study the relationships between hominin foot morphology and environmental context throughout the evolutionary history of hominins, and link the emergence of hominin bipedalism to increases of aridity in Central and Eastern Africa. Carlson et al. (2026) determine relative limb strength in Australopithecus and early members of the genus Homo, interpreted as indicative of frequent arboreal behavior in Australopithecus, as well as indicative of departure of hominins from arboreality by ∼1.8 million years ago. Kurki & Wall-Scheffler (2026) study the variation of pelvic canal dimensions in extant humans and extinct hominins, finding no evidence of a single trajectory of evolution of hominin pelvic shape. Komza, Viola & Schroeder (2026) interpret the evolution of the morphology of hominin midfoot as affected by selection for bipedalism in the lateral side in early bipeds such as Ardipithecus ramidus and shaped by a broad range of evolutionary processes in later hominins.

Sources: en.wikipedia.org

Frequently asked questions

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Why did development of GW501516 stop?

Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.

Does cardarine improve endurance in people?

Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Network